Re­gen­eron stum­bles in PhI Lib­tayo com­bo study as safe­ty con­cerns force sus­pen­sion

Faced with un­ex­pect­ed safe­ty con­cerns, Re­gen­eron has slammed the brakes on a Phase I study test­ing a com­bi­na­tion of its PD-1 drug Lib­tayo and an ear­ly-stage an­ti­body.

The com­pa­ny dis­closed on clin­i­cal­tri­als.gov that the sus­pen­sion is due to a se­vere ad­verse event, but didn’t go any fur­ther. En­roll­ment will be halt­ed and while the pa­tients cur­rent­ly in the tri­al won’t re­ceive ad­di­tion­al treat­ment, they will still be mon­i­tored for safe­ty. End­points News has reached out to the com­pa­ny for more de­tails

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER